A multicenter comparative study of brodimoprim and amoxicillin therapy in the treatment of tonsillopharyngitis in adults.
To compare the efficacy and safety of brodimoprim (BDP) with those of amoxicillin (AMX) in patients with acute bacterial pharyngitis/tonsillitis. Randomized controlled study. Hospital and general practices in Austria, Germany and Switzerland. 519 adult patients of both sexes aged 12 to 75 years. Patients were allocated to an 8- to 12-day treatment with BDP (400 mg loading dose followed by 200mg once a day) or AMX (750mg t.i.d). Resolution of clinical signs/symptoms and negative bacterial examination at completion of therapy. Clinical cure/improvement rate of 97.8% and 94.8% in respectively the BDP and the AMX group. Bacterial eradication in 87.7% of the cases treated with BDP and 88.3% of those receiving AMX. Very good/good tolerability in 85.2% BDP- and 82.8% AMX treated patients.